Eyepoint Pharmaceuticals Inc (EYPT) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Eyepoint Pharmaceuticals Inc stock (EYPT) is currently trading at $13.05. Eyepoint Pharmaceuticals Inc PS ratio (Price-to-Sales) is 35.19. Analyst consensus price target for EYPT is $37.42. WallStSmart rates EYPT as Sell.
- EYPT PE ratio analysis and historical PE chart
- EYPT PS ratio (Price-to-Sales) history and trend
- EYPT intrinsic value — DCF, Graham Number, EPV models
- EYPT stock price prediction 2025 2026 2027 2028 2029 2030
- EYPT fair value vs current price
- EYPT insider transactions and insider buying
- Is EYPT undervalued or overvalued?
- Eyepoint Pharmaceuticals Inc financial analysis — revenue, earnings, cash flow
- EYPT Piotroski F-Score and Altman Z-Score
- EYPT analyst price target and Smart Rating
Eyepoint Pharmaceuticals Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Eyepoint Pharmaceuticals Inc (EYPT) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in institutional own.. Concerns around return on equity and operating margin. Significant fundamental concerns warrant caution or avoidance.
Eyepoint Pharmaceuticals Inc (EYPT) Key Strengths (1)
104.08% of shares held by major funds and institutions
Supporting Valuation Data
Eyepoint Pharmaceuticals Inc (EYPT) Areas to Watch (6)
Company is destroying shareholder value
Losing money on operations
Revenue declining -94.70%, a shrinking business
Very expensive at 35.2x annual revenue
Premium pricing at 3.6x book value
Small-cap company with higher risk but more growth potential
Supporting Valuation Data
Eyepoint Pharmaceuticals Inc (EYPT) Detailed Analysis Report
Overall Assessment
This company scores 19/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 1 register as strengths (avg 10.0/10) while 6 fall into concern territory (avg 1.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own..
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Revenue Growth. Some valuation metrics including Price/Sales (35.19), Price/Book (3.60) suggest expensive pricing. Growth concerns include Revenue Growth at -94.70%, which may limit upside. Profitability pressure is visible in Return on Equity at -72.20%, Operating Margin at -11346.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -72.20% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -94.70% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
EYPT Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
EYPT's Price-to-Sales ratio of 35.19x trades 49% below its historical average of 69.1x (51th percentile). The current valuation is 95% below its historical high of 699.62x set in Mar 2006, and 2215% above its historical low of 1.52x in Oct 2020.
WallStSmart Analysis Synopsis
Data-driven financial summary for Eyepoint Pharmaceuticals Inc (EYPT) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Eyepoint Pharmaceuticals Inc operates as a stable business with moderate growth and solid fundamentals. Revenue reached 31M with 95% decline year-over-year. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Spending 189% of revenue (59M) on R&D, reinforcing its commitment to innovation and future growth.
Revenue contracted 95% YoY. Worth determining whether this is cyclical or structural.
Free cash flow is -66M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Volatility is elevated with a beta of 1.79, so expect amplified moves relative to the broader market.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Eyepoint Pharmaceuticals Inc.
Bottom Line
Eyepoint Pharmaceuticals Inc offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Eyepoint Pharmaceuticals Inc(EYPT)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and markets ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company is headquartered in Watertown, Massachusetts.